|
|
 |
|
Viewing report
|
|
|
|
Strategic Perspectives: Pancreatic Cancer - Gemcitabine Combination Therapy is the Future
Datamonitor, Nov 2002, Pages: 125
Overview
Introduction
Pancreatic cancer has a true survival rate below 3%. As the only drug approved for pancreatic cancer, Lilly’s Gemzar (gemcitabine) is firmly established as the gold standard drug therapy. Developmental drugs are producing excellent trial results in combination with gemcitabine, and it appears that it will remain the drug of choice for the disease with others fighting for use in combination. The overall market is likely to grow as more patent protected drugs are used within the indication.
Scope
Detailed coverage of the patient potential in the seven major markets and analysis of the main unmet needs in the current treatment of the disease
Analysis of the therapeutic management of pancreatic cancer in the seven major markets including opinion leader analysis and input
Overview of drugs in Phase III, II, I and preclinical development
Comprehensive analysis of key phase III products, with Datamonitor forecasts of drug revenues to 2010
Report Highlights
The pancreatic cancer market is currently enjoying slow growth as the uptake of Gemzar continues amongst the prescribing community. However, the market is set for a period of explosive growth as drugs proven to have efficacy in combination with gemcitabine replace cheap generics that are less effective. The launch of new drugs will produce a leap in market value, and this will continue as less toxic drugs are launched.
Reasons to Purchase
Discover why the market for pancreatic cancer therapeutics is set for explosive growth in the next five years
Understand why survival rates for patients with pancreatic cancer are so low, and target this vital area of unmet need
Identify new pharmacological treatments already in the development pipeline that will improve survivability
Improve your knowledge of company strategies in the evolving pancreatic cancer market
DRIVERS AND TRENDS
The pancreatic cancer market is currently enjoying slow growth as the uptake of Gemzar continues amongst the prescribing community. However, the market is set for a period of explosive growth as drugs proven to have efficacy in combination with gemciatbine replace cheap generics that are less effective. The launch of new drugs will produce a leap in market value, and this will continue as less toxic drugs are launched.
INTRODUCTION TO PANCREATIC CANCER
Biology of the disease as well as the etiology, epidemiology and clinical presentation and diagnosis of pancreatic cancer.
TREATMENT STRATEGIES
Analysis of the treatment strategies for pancreatic cancer, including second line drug therapy, in the seven major markets – US, Japan, France, , Germany, Italy, Spain, UK
CURRENTLY AVAILABLE DRUG THERAPIS
Analysis of the currently available therapies commonly used in the treatment of pancreatic cancer, including physician opinion data.
PIPELINE ANALYSIS
Comprehensive overview of drugs in development for pancreatic cancer with an in-depth analysis of phase II and III products.
MARKET FORECASTS
Forecast of future pancreatic cancer drug market growth by product.
DATASETS
Table 1: Key metrics for the HCC drugs market, 2002 & 2010
Table 2: Incidence of pancreatic cancer in the seven major markets, 2002-2010
Table 3: The modified TNM staging classification of The American Joint Committee on Cancer
Table 4: The proportion of pancreatic cancer patients diagnosed at each stage of tumor development in the seven major pharmaceutical markets, 2002
Table 5: Treatment modality used for pancreatic cancer by stage in the seven major pharmaceutical markets, 2002
Table 6: Drug therapies used to treat stage I pancreatic cancer in each of the seven major pharmaceutical markets, 2002
Table 7: Drug therapies used to treat stage II pancreatic cancer in each of the seven major pharmaceutical markets, 2002
Table 8: Drug therapies used to treat stage III pancreatic cancer in each of the seven major pharmaceutical markets, 2002
Table 9: Drug therapies used to treat stage IV pancreatic cancer in each of the seven major pharmaceutical markets, 2002
Table 10: The commonly used radiotherapy schedules for the treatment of pancreatic cancer in the seven major pharmaceutical markets, 2002
Table 11: Radiotherapy schedule usage by disease stage in the seven major pharmaceutical markets, 2002
Table 12: Performance of pancreatic cancer drug therapies as rated by Datamonitor’s global physician panel on five criteria, 2002
Table 13: Drugs in development for pancreatic cancer, 2002
Table 14: Factors impacting pancreatic cancer drug sales in the seven major pharmaceutical markets, 2002--2010
Table 15: Breakdown of commonly used pancreatic cancer drugs, and those forecast to launch within the next eight years, 2002-2010
Table 16: Estimated historical sales of the key pancreatic cancer drugs, 1995-2001
Figure 1: The location of the pancreas in the abdomen
Figure 2: The anatomy of the pancreas
Figure 3: Incidence of pancreatic cancer in the seven major pharmaceutical markets, 2002-2010
Figure 4: The proportion of pancreatic cancer patients diagnosed at each stage of tumor development in the seven major pharmaceutical markets, 2002
Figure 5: Treatment modalities and disease outcome data for stage I pancreatic cancer in the seven major pharmaceutical markets, 2002
Figure 6: Drug therapies used to treat stage I pancreatic cancer in each of the seven major pharmaceutical markets, 2002
Figure 7: Treatment modalities and disease outcome data for stage II pancreatic cancer in the seven major pharmaceutical markets, 2002
Figure 8: Drug therapies used to treat stage II pancreatic cancer in each of the seven major pharmaceutical markets, 2002
Figure 9: Treatment modalities and disease outcome data for stage III pancreatic cancer in the seven major pharmaceutical markets, 2002
Figure 10: Drug therapies used to treat stage III pancreatic cancer in each of the seven major pharmaceutical markets, 2002
Figure 11: Treatment modalities and disease outcome data for stage IV pancreatic cancer in the seven major pharmaceutical markets, 2002
Figure 12: Drug therapies used to treat stage IV pancreatic cancer in each of the seven major pharmaceutical markets, 2002
Figure 13:nd line drug therapy for pancreatic cancer in the seven major markets, 2002
Figure 14: The performance of pancreatic cancer drugs as rated by Datamonitor’s global physician panel, 2002
Figure 15: Unmet clinical need in pancreatic cancer pharmacotherapy, 2002
Figure 16: SWOT analysis of Camptosar
Figure 17: SWOT analysis of Xeloda
Figure 18: SWOT analysis of Eloxatin
Figure 19: SWOT analysis of Gastrimmune
Figure 20: SWOT analysis of Marimastat
Figure 21: SWOT analysis of Virulizin
Figure 22: SWOT analysis of Orathecin
Figure 23: SWOT analysis of Tarceva
Figure 24: SWOT analysis of Alimta
Figure 25: Performance of the pancreatic cancer drug market and key drugs, 2002-2010
Figure 26: Datamonitor’s Healthcare Consultancy
Figure 27: Therapeutic Consulting capabilities
Customers who bought this item also bought
Pancreatic Cancer - Gold Standard Gemcitabine Waiting to be Challenged
Niche Cancers 2001: Pancreatic Cancer
Stakeholder Opinions: Pancreatic Cancer - Gemzar Dominance will Continue among High Levels of Persistent Unmet Needs
Cancer Pancreatic Cancer
Drugs of Tomorrow: Cancer Overview
Strategic Perspectives 2002: Colorectal Cancer Cost Analysis
Br Malls Participacoes Sa
Br. Holdings Corporation
Drugs of Tommorow 2002: Breast Cancer
Treatment Algorithms 2001 Breast Cancer: Herceptin Falling into Stride
Drugs of Tomorrow: Cancer Overview - The synergistic advance: innovatives compliment traditional chemotherapies
Strategic Perspectives 2002: Cancer Adjunct Therapies
|
|
|
|
